text:
Policy Statements and Initiatives
Defra: Local communities are being urged to speak up for their favourite nature areas or suggest where new ones could be created in return for a share of £7.5m to help improve them. A dozen new Nature Improvement Areas (NIAs) will be established, based on the recommendations of local people.
The areas will see rural & urban sites revitalised and turned into bigger, inter-connected networks of wildlife habitats that will range from 10,000 to 50,000 hectares in size. The intention is to re-establish thriving wildlife populations and help species respond to the challenges of climate change. Initial applications will be due by autumn 2011 and more detailed second-stage application by the end of 2011.
Defra is also seeking expressions of interest from local authorities for its Biodiversity Offsetting pilot. This will help developers to follow planning system rules to make good any harm to wildlife, creating new quality habitats or make existing nature sites bigger and better for wildlife. The pilot will run for 2 years from April 2012, providing an opportunity to thoroughly test the offsetting process before a decision is made about whether it could be used across England.
Press release & links ~ Related Natural England PR
BIS: Skills Minister John Hayes has pledged to provide more effective, targeted help for people who face barriers to learning the English language skills communities need. Following the publication of an equality impact assessment of provision for English for Speakers of Other Languages (ESOL) training, which he ordered, Minister Hayes announced that BIS will work in partnership with the Department for Communities and Local Government (DCLG) on developing new forms of support for those who need informal, community-based learning of English.
From August 2011, national provision of full funding for ESOL courses will be focussed on those actively seeking work on Jobseekers Allowance and Employment Support Allowance (Work Related Activity Group). As part of a broader move towards rebalancing the investment in skills between Government, the employer and the learner, other eligible learners or their employers will be expected to make a contribution towards the costs of their ESOL course.
Press release & links ~ IfL comment
DfE: Education Secretary Michael Gove has accepted all the recommendations of Lord Bew's independent review of testing, assessment and accountability at the end of primary school. He said 'the substantial reforms would ensure that heads, teachers, pupils & parents would be able to have confidence in the new system'.
BIS: The Prime Minister has announced that responsibility for the Land Registry, Met Office and Ordnance Survey will pass to the Department for Business, Innovation and Skills (BIS). The Department's Permanent Secretary, Martin Donnelly, welcomed the move, which marks a significant step towards establishment of a Public Data Corporation (PDC), plans for which were announced by the Government in January 2011.
Final decisions on membership, structure and commercial strategy of the Public Data Corporation will be taken later this year, following a consultation on PDC data policy, due to launch over the summer.
Press release & links ~ Related OS press release ~ Related Land Registry PR
DH: The Government will continue to develop a new value-based pricing system that will help NHS patients get better access to innovative medicines Health Secretary Andrew Lansley has confirmed. A Written Ministerial Statement has been laid in the House.
The Government's response to the consultation - A new value-based approach to the pricing of branded medicines - sets out our intention to work with the patients, clinicians, the NHS and the pharmaceutical industry to develop a value-based pricing system that ensures that NHS patients have consistently good access to medicines that they need.
Press release ~ A new value-based approach to the pricing of branded medicines: Government response to consultation
DfE: The Government has published the appointment letter for the new Ministerial Adviser on Adoption.
MoJ: A competition strategy for the management of 9 prisons and the closure of 2 prison sites has been announced recently by the Lord Chancellor and Secretary of State for Justice, Kenneth Clarke.
Press release & links ~ Green Paper, Breaking The Cycle
BIS: Senior experts from the fields of finance, trade & regulation have met to provide insight on the risks caused by technological advances in computer trading for investors, businesses and the public. The meeting brought together representatives from the International Monetary Fund, Bank of England, Bloomberg and Hong Kong Stock Exchange among others and was chaired by Financial Secretary to the Treasury Mark Hoban MP.
The Group will guide the latest Foresight project 'The Future of Computer Trading in Financial Markets'. The project aims to make a contribution to the efficiency, integrity and resilience of financial markets by identifying options for policy makers in the UK and internationally.
Press release ~ Foresight: The Future of Computer Trading in Financial Markets
DH: Plans to transform the care, quality of life & health outcomes for millions of people with respiratory disease have been announced by Health Secretary, Andrew Lansley. Respiratory diseases represent a major problem in England for patients & the NHS. Chronic Obstructive Pulmonary Disease (COPD) is thought to affect more than 3m people in England and more than 5m people currently receive treatment for Asthma.
Press release & links ~ NHS Improvement: Lung
DCMS: A new framework which will allow local television services to be created across the UK was published last week by Secretary of State for Culture, Olympics, Media & Sport Jeremy Hunt. The Government is committed to acting to address the technical & commercial barriers to developing new local TV provision broadcast on Freeview – the digital terrestrial television (DTT) platform.
To make it feasible, Mr Hunt is announcing that a package of geographic interleaved spectrum will be allocated and managed by a new licensed multiplex company. This company will be obliged to build & operate the necessary multiplexes to carry separately licensed local TV services. As previously announced, the infrastructure costs will be met from £25m allocated as part of the television licence fee settlement.
WAG: Wales' Transport Minister, Carl Sargeant, has announced that sustainable transport is to get a boost across Wales by confirming that sustainable travel centres will be allocated £6m over the next year. These centres deliver a range of measures that encourage people to consider using alternatives to the car – such as walking, cycling and public transport.
DCMS: Plans to give Londoners & the Mayor a bigger say in the running of the Capital's eight Royal Parks were set out last week by Heritage Minister John Penrose in a Written Ministerial Statement.
Press release & related links
CO: Plans to create an expensive database of electors are to be abandoned saving taxpayers more than £11m, the Government announced last week. The Co-ordinated Online Record of Electors (CORE) was legislated for in 2006 by the Electoral Administration Act and intended to make it easier for political parties to verify the legitimacy of their donors. The database, which would have been administered by a new independent public body, would have cost an estimated £11.4m to build and £2.7m per annum to run.
IS: Business Minister Edward Davey has published the Government's response to the 'call for evidence' concerning its review of debt advice & personal insolvency.
Press release ~ Consumer Credit and Personal Insolvency: call for evidence & government response
HMT: A plan to deliver at least £1.5bn savings across the 495 operational Private Finance Initiative (PFI) projects in England has been announced. The plans follow pilot projects, which have confirmed savings opportunities of around 5% of annual payments.
A team of PFI experts and specialist negotiators will be drawn from across Government to work around the country to deliver savings. Updated guidance & advice on how savings can be made will be published on the Treasury website to support all PFI contract holders.
DH: NHS patients will have more freedom to choose where they go for their healthcare from April 2012, Health Secretary Andrew Lansley announced last week. To date, choice has only been available in non-urgent hospital care, but new guidance sets out that the choice offer will be extended to community & mental health services for the first time.
Following advice from patient groups, clinicians and voluntary organisations, there are 8 services that have been recommended as the most suitable.
The Department of Health has published 2 documents:
* guidance on how the NHS will deliver greater choice
* the Government response to the consultation on the policy delivering this; Any Qualified Provider (AQP)
Press release ~ Related documents and guidance
HMT: The Government will start formal consultations on increasing public service pension contributions in 2012-13 by the end of this month, Chief Secretary to the Treasury Danny Alexander said last week, as he set out plans for talks on reform to continue into the autumn.
Press release & links ~ PCS union comment
DfE: Early years qualifications are to be reviewed to make sure they are sufficiently rigorous & high quality, Children's Minister Sarah Teather announced last week as part of wider reforms to early education. The Government has also confirmed that 9 local authorities will be the first to trial payment by results for children's centres. They will test rewards for reaching the most vulnerable families, improving family health & wellbeing, and raising attainment of children at age 5.
DfE: The Department for Education has launched its review of personal, social, health & economic (PSHE) education, as outlined in the Schools White Paper. The internal review, which will report to the Secretary of State, will look at the quality of teaching of PSHE in schools, along with its content. Heads, teachers, parents, pupils and other interested parties are invited to submit their views & evidence to the Department.


I was a contributor at TNW for around 8 months, publishing one article a week, before Zee brought me on full-time as UK Editor in May 2011 (very first article as a full-time TNW-er). It really was a life-changing career-shift, and it was a dream job (next to footballer or rock star). Not many people can say they've had a dream job, where 'work' really didn't feel like 'work' at all.
I switched to Apps & Media Editor in early 2012. But in many ways, the job titles have been meaningless – I've had the pleasure of writing about everything at TNW, from consumer-focused startups and gadgets, to company deep-dives and interviews with some of the biggest movers-and-shakers in tech.
I am genuinely sad to say adios to TNW after so long, and will miss everyone greatly. Martin especially has been an awesome boss and Editor-in-Chief, and he'll continue to build something great, along with Boris, Patrick and everyone else in the team.
What's next for me? Well, I'm excited to be taking up an offer to report for VentureBeat, starting today, writing about many of the same kinds of companies and stories I've been writing about for the past few years. There will be some subtle differences in the scope of what I cover, but it's in the same ball-park.


text:
Q: Recursive function for category and sub-category I need help regarding recursive function We have a category table contains category_id,category_name and parent_id:
category_id  category_name  parent_id
------------+--------------+----------
1 Agriculture 0
2 Appearl & Fashion 0
3 Chemicalas 0
4 Plastic & Plastic Products 0
5 Automobile 0
14 Coconut Shell Products 1
15 Nuts & Kernels 1
16 Plant & Animal Oil 1
17 Potpourri 1
18 Raw Cotton & Cotton Waste 1
19 Rice 1
20 Tea 1
21 Seeds 1
22 Vegetable 1
23 White Rice 19
24 Green Rice 19
25 Basmati Rice 19
26 Boiled Rice 19
27 Fresh Preserved Vegetables 22
28 Frozen & Dried Vegetables 22
29 Others 22
30 Activated Carbon 3

We want the output of the category like below using recursive function:
Agriculture > Rice > White rice
Agruculture > Rice > Basmati rice

pls. guide and help me

A: Although it is not quite the same schema you have for the table, this article is very useful for doing something very similar to what it seems you are trying to do.  Have a read and see what you think, it really helped me the first time I tried doing a tree structure like yours.

A: Fairly simple to do in a single call from PHP to MySQL using a non-recursive/adjacency list stored procedure implementation.
Hope it helps :)
Example calls
mysql> call category_hier(1);
+--------+---------------+---------------+----------------------+-------+
| cat_id | category_name | parent_cat_id | parent_category_name | depth |
+--------+---------------+---------------+----------------------+-------+
|      1 | Location      |          NULL | NULL                 |     0 |
|      3 | USA           |             1 | Location             |     1 |
|      4 | Illinois      |             3 | USA                  |     2 |
|      5 | Chicago       |             3 | USA                  |     2 |
+--------+---------------+---------------+----------------------+-------+
4 rows in set (0.00 sec)

mysql> call category_hier(2);
+--------+---------------+---------------+----------------------+-------+
| cat_id | category_name | parent_cat_id | parent_category_name | depth |
+--------+---------------+---------------+----------------------+-------+
|      2 | Color         |          NULL | NULL                 |     0 |
|      6 | Black         |             2 | Color                |     1 |
|      7 | Red           |             2 | Color                |     1 |
+--------+---------------+---------------+----------------------+-------+
3 rows in set (0.00 sec)

$sqlCmd = sprintf("call category_hier(%d);", 1);
$sqlCmd = sprintf("call category_hier(%d);", 2);

Tables and Test data
drop table if exists categories;
create table categories
(
cat_id smallint unsigned not null auto_increment primary key,
name varchar(255) not null,
parent_cat_id smallint unsigned null,
key (parent_cat_id)
)
engine = innodb;

insert into categories (name, parent_cat_id) values
('Location',null),
('Color',null),
   ('USA',1),
      ('Illinois',3),
      ('Chicago',3),
   ('Black',2),
   ('Red',2);

Stored procedure
drop procedure if exists category_hier;

delimiter #

create procedure category_hier
(
in p_cat_id smallint unsigned
)
begin

declare v_done tinyint unsigned default 0;
declare v_depth smallint unsigned default 0;

create temporary table hier(
 parent_cat_id smallint unsigned,
 cat_id smallint unsigned,
 depth smallint unsigned default 0
)engine = memory;

insert into hier select parent_cat_id, cat_id, v_depth from categories where cat_id = p_cat_id;
create temporary table tmp engine=memory select * from hier;

/* http://dev.mysql.com/doc/refman/5.0/en/temporary-table-problems.html */

while not v_done do

    if exists( select 1 from categories c
        inner join hier on c.parent_cat_id = hier.cat_id and hier.depth = v_depth) then

        insert into hier select c.parent_cat_id, c.cat_id, v_depth + 1 from categories c
            inner join tmp on c.parent_cat_id = tmp.cat_id and tmp.depth = v_depth;

        set v_depth = v_depth + 1;

        truncate table tmp;
        insert into tmp select * from hier where depth = v_depth;

    else
        set v_done = 1;
    end if;

end while;

select
 c.cat_id,
 c.name as category_name,
 p.cat_id as parent_cat_id,
 p.name as parent_category_name,
 hier.depth
from
 hier
inner join categories c on hier.cat_id = c.cat_id
left outer join categories p on hier.parent_cat_id = p.cat_id
order by
 hier.depth;

drop temporary table if exists hier;
drop temporary table if exists tmp;

end #

delimiter ;

A: Something like?
function recursiveCategory($categoryId) {
    // Some code to get category from the database resulting in Category-array
    $content = $Category["category_name"];
    if($Category["category_parent"] == 0) {
        $content .= " > ".$recursiveCategory($Category["category_parent"]);
    }

    return $content;
}

Also, don't use the value 0 in parent_id if the category does not have a parent. Use null instead.

redpajama_set_name: RedPajamaStackExchange


HOUSTON, TX, Jan 8, 2018 – Musician, singer and songwriter Tariq Aidid announced that he will be performing live in concert during his EP premier release party on April 21st, 2018 at Czech Center Museum Houston located at 4920 San Jacinto Street, Houston, Texas 77044 from 8pm to 10pm. The evening will be a ticketed event featuring amazing music, complimentary hors d'oeuvres and beverages, vendor opportunities and a silent auction. Event sponsorship opportunities are available!
Tariq discovered at the age of 10 that he had the talent to sing and play the drums, guitar and keyboard. He took to those instruments naturally, but formed an inseparable bond with the guitar. At the age of 19, Tariq started playing professionally and has performed at many different venues and special events around Houston including most recently the 2nd Annual Total Package Awards held at the Budweiser Brewery Experience and the Ebony Magazine NFL Superbowl Houston Event during Superbowl LI. At a young age Tariq even caught the attention of Houston music industry icon, Mathew Knowles saying, "Tariq's musicianship and stage presence is incredible". Tariq has even opened for various artists such as Sun Seeker America Band, K-Ci & JoJo, Fantasia and Tony! Toni! Toné!
Now, having honed his musical talents and cultivated fresh material, at only 24 years of age, Tariq is ready to give the citizens of Houston an amazing show they will never forget! Demonstrate your support and join Tariq for a wonderful evening of fun, entertainment and music to soothe your soul.


text:
Titanfall: The Trials and Tribulations of Long-Term Multiplayer Enjoyment
Respawn Entertainment's online shooter has plenty of room to grow but will players let it?
Posted By Ravi Sinha | On 13th, Feb. 2014 Under Article, Editorials
When Mass Effect 3's multiplayer mode was first introduced, there was collective curiosity as to how Bioware would go about taking its predominantly story-based action RPG online. This was before the entire controversy regarding the ending erupted and for most, the result was a simple but still fun and addictive past-time. EA's Origin might ruin it with connectivity issues and bugs – that still persist to this day (eat your heart out, Battlefield 4) – but it's still an excellent multiplayer experience.
"But the concerns won't go away for those who look at it as a typical first person shooter experience that doesn't have much new to offer. "This was supposed to be the next big thing – why isn't it exciting me right off the bat?""
Now imagine Bioware had to make a multiplayer mode for Mass Effect 4. Imagine if they allowed you to not only play as Alliance Forces but also as the enemy waves attacking. Imagine if they introduced new modes, new maps, and a mix of AI enemies to make things a bit more challenging for both sides and story-based objectives to give the game a more rounded feel. It's Mass Effect, naturally, so there would be excitement – especially since Bioware handled both the story and multiplayer so well.
And while that isn't happening (yet), it's amazing that Respawn Entertainment's Titanfall could be so routinely criticized for introducing what is essentially a story-based multiplayer experience. That too, with giant robots. Giant robots should make anything critic-proof (unless your name is Michael Bay and you're ruining Transformers) but alas, skeptics still find problems with Titanfall's overall approach. Even if the meat of the game is more about countering the other person's counter and looking cool while doing it, giant robots or no.
The beta has also come rolling along and there are concerns as to whether the AI opponents are at all worth it. What about the resolution, which isn't at 1080p? The battlefield looks kind of barren with only 12 players fighting each other; forget the utter chaos induced by some of the mechs. You could chalk all this up to Titanfall still being in the beta phase – and most players do. But the concerns won't go away for those who look at it as a typical first person shooter experience that doesn't have much new to offer. "This was supposed to be the next big thing – why isn't it exciting me right off the bat?"
"Respawn could and most likely will add more Titans and classes down the line. It could add new AI soldiers to further increase the challenge for players who are finding the current Grunts too easy to dispose of. It could up the player count depending on the overall feedback and stability. "
When taken as a slice of what the game is capable of though, it's easy to see that Titanfall succeeds. Does it offer seamless mech action and foot-soldiering mixed up with frantic combat that feels familiar yet operates wholly different? It does. It's just like Mass Effect 3's multiplayer – you may think you know what it's like to run around and murder various Geth/Collectors/Reapers/Cerberus as Commander Shepard but multiplayer introduces a whole new dimension to the proceedings. You're suddenly running around as a Fury Adept and blowing enemies up with biotic explosions. You're working to earn Premium Spectre Packs and getting screwed every time by an existing weapon upgrade for a gun you don't use rather than getting that Cerberus Harrier you want so badly.
But when players first experienced the demo – or the multiplayer selection as it released – you didn't have a wide spread of planets to visit. The class selection can only be described as sparse and don't get us started on the weapons. Were people still having fun with it? They were. Why? Because it was a brand new way to look at the game and at multiplayer in general, despite being so utterly so simple. Cue the "deceptively simple but insanely complex" line here.
Such is the case with Titanfall. Unlike Mass Effect 3, we truly haven't seen what the full game will offer at launch. Respawn could and most likely will add more Titans and classes down the line. It could add new AI soldiers to further increase the challenge for players who are finding the current Grunts too easy to dispose of. It could up the player count depending on the overall feedback and stability.
"If you want instant satisfaction and a more visual indication of your progress, there's Call of Duty: Ghosts and Battlefield 4. They'll satisfy your thirst for action while making you feel like you're doing something."
And as players play more of the game, they'll begin to discover just how different it is in terms of movement. Just how different was Team Fortress 2 for you when you discovered how useful the Soldier's Rocket Jump was? Something similar could happen with Titanfall's jetpack mechanics. All it needs is time.
It's normal to criticize a multiplayer product for not immediately wowing you in the first hour. You're going to be investing your time into this so it better be fun. The real fun doesn't come from instant satisfaction in these kinds of games. It comes with learning the game and using what you've learned to outsmart your competition. Then you add giant robots to the mix because, why aren't people raving about the giant robots?
If you want instant satisfaction and a more visual indication of your progress, there's Call of Duty: Ghosts and Battlefield 4. They'll satisfy your thirst for action while making you feel like you're being rewarded quickly. But if you want something a bit more substantial, it might be wise to wait and watch for games like Titanfall. They could yet surprise you.
Tagged With: beta, EA, Mass Effect 3, multiplayer, pc, respawn entertainment, Team Fortress 2, TitanFall, xbox 360, Xbox One
Publisher: EA
Platforms: Xbox One, Xbox 360, PC
The Medium is Looking Impressive in Extended Gameplay Demo
What Remains of Edith Finch, Torchlight 3, and More Coming to Xbox Game Pass in January
PS5's "Significantly Higher" Performance "Brings Many Improved Functions" Over PS4 – Dying: 1983 Dev
Analysts Speculate Switch Could Be Best Selling System Of 2021 With Potential New Revision
Atomic Heart PC Requirements Revealed

redpajama_set_name: RedPajamaCommonCrawl


The weather was pretty nice.. We piddled around in the morning, then around 11:30 Muscle Man decided he wanted to run our long run, pushing the boys?!?!?! I was a little baffled since I already had Tall Grandma on the line to watch the boys the next morning… And I knew that Muscle Man would need to eat soon… Hmmmm… Not to get in his way, I got snacks ready and we set out..
***I had originally thought of Honey Bucket Inspectors, but Muscle Man came up with a more feminine name..
>>>>Back to the run, we set out and the boys were FUSSY!! And by boys I mean all 3. Poor Muscle Man had a cramp in his side and was SUPER HUNGRY (Did I call it or what?) I knew there was no way we would get in a long run, but we could salvage a few miles.. We went out half way and then took the little trail to the river so the boys could toss in some sticks, the ice/snow storm in January had knocked down trees across the path. I got a few scrapes in the effort but didn't realize until we got home.
We turned back, 4 miles done… good news is we would have fresh legs for the long run take #2 the next day..
Tall Grandma watched the boys (thanks Mom!!) so we opted to start from the Orting Park. The trail was busy busy with people, bikers and runners. It was a strange mix, almost like there were trainers with their clients. We also saw 5 couples, which was very cool. There was a group of 3 well-dressed women on bikes, one lady complimented my grey Sugoi jacket…they stopped to check out the area that looks like a Beaver created it, but there is no Beaver, we ran past.. As they sped by again they asked what we were training for… on their return trip they cheered us on, very nice!!
I wore a jacket like a dope, not needed in 55', so I took it off when I stopped to admire a large bullfrog in the marshy area next to the trail. The goal was to run 11-12 miles, when we got around the turn MM picked 12!! About the mid way point we saw a older-looking man on the street which parallels the trail, he was jogging, wearing a stocking cap, sweats and sweatshirt… he stopped, looked both ways then dropped and started doing pushups.. VERY STRANGE!
6.0 miles done, half way… MM had his Chocolate Gu, I had a couple chomps, we both drank from our handhelds, and off we went. The return trip is a slight decent, which felt really good. We saw some of the usual people, funny how you get to 'know' people if you run a path enough… Having a high metabolism is tough, my poor hubby was pretty depleted toward the end. I mentioned that there was a McDonald's near the trail head…pretty sure he ran the last mile for FOOD.. Our final mile was the fastest of the run..
I am happy to report that I (we) have run over 100 miles for the month!! Gotta love sticking (sort of) to a training plan!! 2 longs runs left before MM's first Half on May 20th!!
CONGRATS to all of you who raced last weekend.. With Eugene, Big Sur and other races there was a lot going on. I am PUMPED it is racing season!!!
Great job on your 12 miler! That Ranier to Ruston Race sounds fun. I will have to remember it for next year. It is the same day as the NODM half.
Congrats on 100 miles and your Honey Bucket "sponsorship". I love it!
I finished with 98 miles for April. Honestly.
love the honey bucket signs. Never gets old to me. Always makes me smile.
but honestly the 12 with your husband . . . that's so awesome.
Honey Buckets is hysterical. Congrats on the 12 miler.
I love that name...and I think you all will have a blast!
Good luck to Muscle Man!
Love that you have got to spend 100 miles together!! So stinking awesome!!!
I like on FB and follow your blog.


Illustrious all the way or Hermes.
Little appears known of the origins of this name to the general public.
Acasta was one of the 3000 goddess nymphs, or Oceanides, daughter of Oceanus and Tethys. Acasta is associated with water movements.
The literal translation can be more sinister. Unstable or unpredictable.
It was on the 8th June 1940 that Admiral Marschall in his flagship Gneisenau, with sister Scharnhorst during operation Juno, discovered how unpredictable sea warfare could be when HMS Acasta, whilst escorting the already sinking carrier HMS Glorious, turned the tables on the Germans and placed 1 fish squarely into Scharnhorst, whose dead totaled 48.
Acasta slipped beneath the seas, following her sister Ardent and the Glorious.
Marschall ordered the twins ensigns be lowered to half mast, prayers and thoughts to be extended to their valiant deceased foe.
The men who manned and died in HMS Acasta.
Truly an unpredictable outcome. There is no beauty in death, whatever name your ship has.
Japanese ships. So poetic, yet so warlike to those willing to figure out what they mean.
Second place goes to the British. Such fearsome names: Invincible, Glourious, Indefatigable, Warrior..so long as they were not ironic.
The Japanese got many well named destroyers.
Hibiki (echo),Shigure(drizzle),which are also common girl names.
Yes. Compare the conduct of Marshall with that of some of the Waffen SS units who routinely murdered British, Canadian and US prisoners of war simply because they had put up a fight before they surrendered to them.


text:
Contact Us Global Locator
California Compliance Law
Manufacturing at Genzyme
Resources for Health Care Professionals
Reporting Side Effects
Working with Patient Organizations
Patient Access to Treatment
Building Sustainable Health Care
Contributions and Giving
Applying for a Contribution
Employee Involvement
The Job Application Process
Corporate Organization and Roles
Recruiters and Staffing Agencies
Global Locator
About Leadership Areas of Focus
News Stories Corporate Compliance
Product Portfolio Manufacturing at Sanofi Genzyme Resources for Health Care Professionals
Patient Support Services Reporting Side Effects Working with Patient Organizations
Patient Access to Treatment Contributions and Giving
Job Search Employment Benefits Culture and Values
Career Development Diversity EEO is the Law
E-MailPrint Share Text Size
About Genzyme
Kevzara® (sarilumab) data at the 2018 ACR/ARHP Annual Meeting provide additional insight on safety, efficacy in rheumatoid arthritis
*Among 13 Alliance presentations, late-breaker poster will highlight potential for IL-6 levels to serve as a biomarker to help predict treatment response
Friday, October 19, 2018 8:57 am EDT
Dateline:
Bridgewater, N.J. and Tarrytown, N.Y.
EmailPDFPrint
Data from analyses of the Kevzara® (sarilumab) Phase 3 clinical development program will be presented at the 2018 ACR/ARHP Annual Meeting, which is being held in Chicago from October 19 to 24.
A late-breaking poster presentation will discuss new post-hoc analyses from the positive Phase 3 MONARCH and MOBILITY RA trials, which have previously reported results showing Kevzara significantly improved efficacy over two commonly-used RA therapies. The new analyses show patients with high baseline levels of interleukin 6 (IL-6) had higher disease activity and joint damage at baseline and showed a greater response to Kevzara 200 mg compared to either methotrexate (MTX) alone or adalimumab than patients with low IL-6 levels.
In the MOBILITY trial, patients with high IL-6 levels treated with Kevzara were more likely to demonstrate improvement in clinical signs and symptoms and had less joint damage according to radiographic assessment versus those with high IL-6 levels treated with MTX alone. In the MONARCH trial, patients with high IL-6 levels treated with Kevzara were more than 30 times as likely to achieve a measure of disease remission (disease activity score in 28 joints with an erythrocyte sedimentation rate less than 2.6) at week 24 compared to those treated with adalimumab (odds ratio 33.9 [unadjusted 95% CI 3.5, 328.7]). The incidence of treatment-emergent adverse events was similar in patients in the low, medium and high IL-6 groups. In Phase 3 clinical trials, the most common adverse reactions (incidence at least 2 percent) with Kevzara were neutropenia, increased ALT (a liver enzyme), injection site erythema, upper respiratory infections and urinary tract infections.
"The analysis of these Phase 3 data provides a look at the utility of biomarkers and their potential role in optimizing treatment choices for patients with RA," said Jonathan Sadeh, M.D., Vice President, Immunology and Inflammation Development Franchise, Sanofi. "We look forward to uncovering new insights that can help support physicians in their efforts to identify the right treatment plan for each patient with RA."
"It makes sense that patients with the highest level of IL-6 would respond best to a therapy that specifically inhibits this pathway – however, it's very exciting for the first time to have actual data supporting this concept. The application of biomarkers to predict response to different types of therapy could herald a new precision management approach to RA," said Bolanle Akinlade, M.D., Vice President, Clinical Sciences, Regeneron. "We are initiating additional Kevzara clinical trials in 2019 that will include the prospective evaluation of IL-6 levels as a predictor for treatment response. We believe this may have important future implications for personalized RA patient care."
Use of IL-6 as a biomarker has not been reviewed by any regulatory authority.
Additional insight on Kevzara for the treatment of RA
Data being presented at ACR also include three oral presentations, describing Kevzara safety and efficacy data for patients with low absolute neutrophil counts; and health economics and outcomes research data focusing on tumor necrosis factor (TNF) inhibitor versus non-TNF inhibitor treatment switching trends; as well as comparative effectiveness of first-line TNF inhibitor treatment versus non TNF inhibitor treatment in patients who had not been on a biologic disease-modifying antirheumatic drug (bDMARD).2-4
Kevzara is a fully-human monoclonal antibody that binds specifically to the IL-6 receptor, and has been shown to inhibit IL-6-mediated signaling.5 IL-6 is a signaling protein produced in increased quantities in patients with RA and has been associated with disease activity, joint destruction and other systemic problems.6-10
Sanofi and Regeneron presentations include the following 10 poster presentations and three oral presentations:
Sunday, October 21 to Tuesday, October 23 (Late-Breaking Poster)
High Baseline Serum IL-6 Identifies a Subgroup of Rheumatoid Arthritis Patients with Rapid Joint Damage and Clinical Progression and Predicts Increased Sarilumab Treatment Response
Anita Boyapati, 9:00-11:00AM (Late-breaking abstract poster presentation 9:00-11:00AM on Tuesday, October 23)
Exploring the Effects of Depressive Symptoms on the Efficacy of Sarilumab and Improvements in Health-Related Quality of Life
Vibeke Strand, 9:00-11:00AM
Unique Changes in Hemoglobin with Sarilumab Versus Adalimumab Are Independent of Better Disease Control in Patients with Rheumatoid Arthritis (RA)
Gerd R. Burmester, 9:00-11:00AM
Pain Is Improved in Around 50% of Patients and Fatigue in 40% of Patients with Rheumatoid Arthritis Treated with Sarilumab in the Target, Mobility and Monarch Trials
Laure Gossec, 9:00-11:00AM
The Relationship between Lipid Profile Changes and Inflammation across the Phase 3 Sarilumab Rheumatoid Arthritis (RA) Developmental Program
Christina Charles-Schoeman, 9:00-11:00AM
Reductions in Absolute Neutrophil Count (ANC) with Sarilumab Resulting in Dose Delays or Dose Decreases: Effects on Efficacy and Safety
Jeffrey R. Curtis, 5:45-6:00PM
Long-Term Safety with Sarilumab Plus Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) and Sarilumab Monotherapy in Rheumatoid Arthritis (RA): An Integrated Analysis with 9,000 Patient-Years (Pt-Yrs) of Follow-up
Roy Fleischmann, 9:00-11:00AM
Long-Term Treatment with Sarilumab Plus Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs): Pooled Safety and Efficacy with over 4 Years' Treatment
Mark C. Genovese, 9:00-11:00AM
Liver Function Test Levels with Sarilumab Treatment in Phase 3 Trials: Analysis By Baseline Liver Function Test (LFT) Level
John Tesser, 9:00-11:00AM
Patient-Reported Benefits of Sarilumab Monotherapy in Adult Patients with Active Rheumatoid Arthritis: Results from an Open-Label Extension Study
The Impact of Rheumatoid Arthritis on Patient-Reported Outcomes: Comparison between Sarilumab Clinical Trials and Real-World Patient Data
Identifying Trends in Lines of Therapy Following Initial Biologic Disease-Modifying Antirheumatic Drug in Patients with Rheumatoid Arthritis
Jay Lin, 4:45-5:00PM
The Comparative Effectiveness of First-Line Tumor Necrosis Factor Inhibitor (TNFi) Compared with Non-TNFi Agents in Patients with Rheumatoid Arthritis: Results from the Corrona Registry
Dimitrios A. Pappas, 5:15-5:30PM
In the U.S., Kevzara is indicated for the treatment of adult patients with moderately to severely active RA who have had an inadequate response or intolerance to one or more disease modifying antirheumatic drugs, such as MTX. Kevzara was developed and is commercialized under a collaboration between Sanofi and Regeneron.
Kevzara can cause serious side effects including:
SERIOUS INFECTIONS: Kevzara is a medicine that affects your immune system. Kevzara can lower the ability of your immune system to fight infections. Some people have serious infections while using Kevzara, including tuberculosis (TB), and infections caused by bacteria, fungi, or viruses that can spread throughout the body. Some people have died from these infections.
Before starting Kevzara, tell your healthcare provider if you:
think you have an infection or have symptoms of an infection, with or without a fever, such as sweats or chills, muscle aches, cough, shortness of breath, blood in phlegm, weight loss, warm, red or painful skin or sores on your body, diarrhea or stomach pain, burning when you urinate or urinating more often than normal or feel very tired; or are being treated for an infection, get a lot of infections or have repeated infections
have diabetes, HIV, or a weakened immune system.
have TB, or have been in close contact with someone with TB
live or have lived, or have traveled to certain parts of the country (such as the Ohio and Mississippi River valleys and the Southwest) where there is an increased chance of getting certain fungal infections (histoplasmosis, coccidioidomycosis, or blastomycosis)
have or have had hepatitis
After starting Kevzara, call your healthcare provider right away if you have any symptoms of an infection.
CHANGES IN CERTAIN LABORATORY TEST RESULTS: Your healthcare provider should do blood tests before and after starting Kevzara to check for low neutrophil (white blood cells that help the body fight off bacterial infections) counts, low platelet (blood cells that help with blood clotting and stop bleeding) counts, and an increase in certain liver function tests. Changes in test results are common with Kevzara and can be severe. You may also have changes in other laboratory tests, such as your blood cholesterol levels.
TEARS (PERFORATION) OF THE STOMACH OR INTESTINES: Some people using Kevzara get tears in their stomach or intestine. Call your healthcare provider right away if you have fever and stomach (abdominal) pain that does not go away.
CANCER: Kevzara may increase your risk of certain cancers by changing the way your immune system works. Tell your healthcare provider if you have ever had any type of cancer.
SERIOUS ALLERGIC REACTIONS: Serious allergic reactions can happen with Kevzara. Get medical attention right away if you have any of the following signs: shortness of breath or trouble breathing; feeling dizzy or faint; swelling of the lips, tongue or face; moderate to severe stomach (abdominal) pain or vomiting; or chest pain.
Do not use Kevzara if you are allergic to Sarilumab or any of the ingredients of Kevzara.
Before using Kevzara, tell your healthcare provider if you:
have an infection
have liver problems
have had stomach (abdominal) pain or a condition known as diverticulitis (inflammation in parts of the large intestine) or ulcers in your stomach or intestines
recently received or are scheduled to receive a vaccine. People who take Kevzara should not receive live vaccines.
plan to have surgery or a medical procedure
are pregnant or plan to become pregnant. It is not known if Kevzara will harm your unborn baby
are breastfeeding or plan to breastfeed. Talk to your healthcare provider about the best way to feed your baby if you use Kevzara. It is not known if Kevzara passes into your breastmilk.
take any medicines, including prescription and nonprescription medicines, vitamins, and herbal supplements. Especially tell your healthcare provider if you use any other medicines to treat your RA. Using Kevzara with these medicines may increase your risk of infection.
The most common side effects include:
injection site redness
upper respiratory tract infection
nasal congestion, sore throat, runny nose
These are not all the possible side effects of Kevzara. Tell your doctor about any side effect that bothers you or does not go away. You are encouraged to report negative side effects of prescription drugs to the FDA at www.fda.gov/medwatch or call 1-800-FDA-1088 or to Sanofi-Aventis at 1-800-633-1610.
To learn more, talk about Kevzara with your healthcare provider or pharmacist. The FDA-approved Medication Guide and Prescribing Information can be found at Kevzara.com or by calling 1-844-Kevzara (1-844-538-9272).
Please click here for full prescribing information including risk of SERIOUS SIDE EFFECTS and Medication Guide
About Regeneron
Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to seven FDA-approved treatments and numerous product candidates in development, all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neuromuscular diseases, infectious diseases and rare diseases.
Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite® technologies, such as VelocImmune® which produces optimized fully-human antibodies, and ambitious research initiatives such as the Regeneron Genetics Center, which is conducting one of the largest genetics sequencing efforts in the world.
For additional information about the company, please visit www.regeneron.com or follow @Regeneron on Twitter.
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates regarding the marketing and other potential of the product, or regarding potential future revenues from the product. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans" and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, unexpected regulatory actions or delays, or government regulation generally, that could affect the availability or commercial potential of the product, the absence of guarantee that the product will be commercially successful, the uncertainties inherent in research and development, including future clinical data and analysis of existing clinical data relating to the product, including post marketing, unexpected safety, quality or manufacturing issues, competition in general, risks associated with intellectual property and any related future litigation and the ultimate outcome of such litigation, and volatile economic conditions, as well as those risks discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2017. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.
Regeneron FLS
This news release includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company"), and actual events or results may differ materially from these forward-looking statements. Words such as "anticipate," "expect," "intend," "plan," "believe," "seek," "estimate," variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. These statements concern, and these risks and uncertainties include, among others, the nature, timing, and possible success and therapeutic applications of Regeneron's products, product candidates, and research and clinical programs now underway or planned, including without limitation Kevzara® (sarilumab) for the treatment of moderately to severely active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to, one or more disease modifying anti-rheumatic drugs or other potential indications; the likelihood, timing, and scope of possible regulatory approval and commercial launch of Regeneron's late-stage product candidates and new indications for marketed products (such as Kevzara); unforeseen safety issues resulting from the administration of products and product candidates (such as Kevzara) in patients, including serious complications or side effects in connection with the use of Regeneron's product candidates in clinical trials; the extent to which the results from the research and development programs conducted by Regeneron or its collaborators may be replicated in other studies and lead to therapeutic applications; ongoing regulatory obligations and oversight impacting Regeneron's marketed products (such as Kevzara), research and clinical programs, and business, including those relating to patient privacy; determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron's ability to continue to develop or commercialize Regeneron's products and product candidates, including without limitation Kevzara; competing drugs and product candidates that may be superior to Regeneron's products and product candidates; uncertainty of market acceptance and commercial success of Regeneron's products and product candidates and the impact of studies (whether conducted by Regeneron or others and whether mandated or voluntary) on the commercial success of Regeneron's products and product candidates, including without limitation Kevzara; the ability of Regeneron to manufacture and manage supply chains for multiple products and product candidates; the ability of Regeneron's collaborators, suppliers, or other third parties to perform filling, finishing, packaging, labeling, distribution, and other steps related to Regeneron's products and product candidates; the availability and extent of reimbursement of the Company's products (such as Kevzara) from third-party payers, including private payer healthcare and insurance programs, health maintenance organizations, pharmacy benefit management companies, and government programs such as Medicare and Medicaid; coverage and reimbursement determinations by such payers and new policies and procedures adopted by such payers; unanticipated expenses; the costs of developing, producing, and selling products; the ability of Regeneron to meet any of its financial projections or guidance and changes to the assumptions underlying those projections or guidance; the potential for any license or collaboration agreement, including Regeneron's agreements with Sanofi, Bayer, and Teva Pharmaceutical Industries Ltd. (or their respective affiliated companies, as applicable), to be cancelled or terminated without any further product success; and risks associated with intellectual property of other parties and pending or future litigation relating thereto, including without limitation the patent litigation proceedings relating to EYLEA® (aflibercept) Injection, Dupixent® (dupilumab) Injection, and Praluent® (alirocumab) Injection, the ultimate outcome of any such litigation proceedings, and the impact any of the foregoing may have on Regeneron's business, prospects, operating results, and financial condition. A more complete description of these and other material risks can be found in Regeneron's filings with the U.S. Securities and Exchange Commission, including its Form 10-Q for the quarterly period ended June 30, 2018. Any forward-looking statements are made based on management's current beliefs and judgment, and the reader is cautioned not to rely on any forward-looking statements made by Regeneron. Regeneron does not undertake any obligation to update publicly any forward-looking statement, including without limitation any financial projection or guidance, whether as a result of new information, future events, or otherwise.
Regeneron uses its media and investor relations website and social media outlets to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Regeneron is routinely posted and is accessible on Regeneron's media and investor relations website (http://newsroom.regeneron.com) and its Twitter feed (http://twitter.com/regeneron).
Boyapati, A. et al. (October 2018). High baseline serum IL-6 identifies a subgroup of rheumatoid arthritis patients with rapid joint damage and clinical progression and predicts increased sarilumab treatment response. Poster session presented at the meeting of the American College of Rheumatology, Chicago, IL.
Curtis, JR. et al. (October 2018). Reductions in absolute neutrophil count (ANC) with sarilumab resulting in dose delays or dose decreases: effects on efficacy and safety. Oral session presented at the meeting of the American College of Rheumatology, Chicago, IL.
Lin, J. et al. (October 2018). Identifying trends in lines of therapy following initial biologic disease-modifying antirheumatic drug in patients with rheumatoid arthritis. Oral session presented at the meeting of the American College of Rheumatology, Chicago, IL.
Pappas, DA. et al. (October 2018). The comparative effectiveness of first-line tumor necrosis factor inhibitor (TNFi) compared with non-TNFi agents in patients with rheumatoid arthritis: results from the Corrona registry. Poster session presented at the meeting of the American College of Rheumatology, Chicago, IL.
Kevzara Prescribing Information. Sanofi and Regeneron Pharmaceuticals, Inc. April 2018.
Choy E. Understanding the dynamics: pathways involved in the pathogenesis of rheumatoid arthritis. Rheumatol. 2012;51(suppl 5):v3-v11.
Dayer J., Choy E. Therapeutic targets in rheumatoid arthritis: the Inerleukin 6 receptor. Rheumatol. 2010;49:15-24.
Choy, E. H. et al. The problem of choice: current biologic agents and future prospects in RA. Nat Rev Rheumatol. 2013;9:154-63.
Choy, E, Calabrese, H. Neuroendocrine and neurophysiological effects of interleukin 6 in rheumatoid arthritis Rheumatol. 2017;1-11. doi:10.1093/rheumatology/kex391.
Srirangan, S., Choy, E.H. The role of Interleukin 6 in the pathophysiology of rheumatoid arthritis. Ther Adv Musculoskel Dis. 2010;2(5):247-56.
Sanofi Media Relations
Sanofi Investor Relations
Regeneron Media Relations
Sarah Cornhill
Sarah.Cornhill@regeneron.com
Regeneron Investor Relations
Genzyme Corporation
500 Kendall Street
Congrats to this amazing team!!! https://t.co/NphatVWy9R-4 days 11 hours ago
The FDA will review our investigational treatment for relapsed/refractory #multiplemyeloma, an incurable #cancer of… https://t.co/tnYHxYrU64-6 days 13 hours ago
Acquired thrombotic thrombocytopenic purpura (#aTTP) can affect up to 6 in 1,000,000 people. Visit us #ISTH2019, bo… https://t.co/aGA6PEwRi7-1 week 23 hours ago
#ISTH2019 is in full swing and our team has a lot going on! Stop by booth 910 to learn more about our work in… https://t.co/ofvVMhyfTB-1 week 1 day ago
Stop by our #ISTH2019 booth 910 to learn more about acquired thrombocytopenic purpura (#aTTP) https://t.co/31x7Za7KnM-1 week 1 day ago
Contact Us | Terms of Use | Privacy Policy | Site Map
This site is intended for United States residents only.
© Genzyme Corporation, a Sanofi company. All rights reserved.
Genzyme is registered in U.S. Patent and Trademark Office.
Business Wire NewsHQ℠


Continuous improvement is an organisational culture. Ever since the Japanese led the way in the 1950s and stunned the West with their meteoric rise in commercial success, driven by an attention to quality and efficiency in manufacturing that was unprecedented, many organisations have adopted and reaped the benefits of a culture of continuous improvement. This is a culture, led from the very top management level, in which all employees are empowered to identify and implement ways of improving their outputs.
The Americans were quick to learn from the early Japanese pioneers and many leading exponents of continuous improvement, or "quality gurus" as they soon became known, came from Japan or the US. These people (amongst whom two of the more famous were W Edwards Deming of the US and Dr Kaoru Ishikawa of Japan) visited each other's countries and widely shared their learning and experience, which has now spread throughout the world.
The test of time has shown that a continuous improvement culture benefits not only manufacturing organisations, but also service industries and not-for-profit organisations. It makes employees feel valued and motivated, delights customers and makes processes more effective and less costly to operate.
W Edwards Deming of the US promoted the "Plan Do Check Act" cycle (see above), a systematic approach to problem solving and improvement activity, that is nowadays incorporated into many of the ISO management system standards.
Dr Kaoru Ishikawa of Japan introduced the "Ishikawa Diagram" (also known as the "Fishbone" or "Cause & Effect" diagram), a tool for systematically representing and analysing the real causes behind a problem or effect.
These are just two of a wide range of tools and techniques in use today, too numerous to list here.


Was the first time eating the delicious and anxious, but very good. Intact also mildew even blackened, ochazuke is fit as the tea tasty, and it has really good shopping. Toasty. Delicious and so easy to eat, even into the yogurt. And hearty... in small doses, diet may! It is delicious. Feel the sweet taste as you bite. It is naturally gentle sweetness. If 鳩麦 is so very good skin, so skin is still good. To the students from terrible stress in skin roughness. Improved a little. Caramelized Onion met during their stay and are looking for here. Polipoli daily to eat a handful or so. Enzymes and collagen drink, cleansing soaps and cosmetics are choosing this because indiscriminately "thanks to job's tears! ' And the like becomes impossible almost new breakouts began eating job's tears still scarce. Has a tone better than when only the enzymes and collagen. I'll stick longer.
an iframe capable browser in please please.
Today also thanks to orders from around the country.
* Additional shipping fee is included of frozen, chilled and please be careful.
*Please bear (fee payable to the bank of our side and commissions paid to your bank side) fee required in order to transfer money.


Is to change the type of pasta or to add to the other ingredients during the preparation, there are various recipes of minced meat with dough to try out.
Looking for ideas for lunch or dinner?
Do not despair because we have what you need.
On the menu we have suggestions of recipes of minced meat with dough.
Blog Food From Portugal is a simple variation of the traditional recipe of minced meat with dough.
Salt, pepper, nutmeg and grated cheese q. b.
Start by mixing the two types of minced meat and season with salt, pepper, minced garlic and nutmeg.
After, heat the olive oil, two chopped onions and tomatoes without skin and cut into small pieces and let it simmer over a low heat until the tomatoes get broken.
Then, add the minced meat and cook on a low heat for about 20 minutes, stirring occasionally. When the meat is cooked turn off the heat, sprinkle with chopped parsley and set aside.
While it comes to the meat, also bring the heat (high) a pan with water seasoned with salt and a small onion, peeled. When the water begins to boil, reduce to heat to medium-low, add the pasta and let it cook for about 10 minutes. When the pasta is cooked, drain it and reserve.
In a bowl, mix the cream with the Béchamel. Then, on a tray, place a layer of batter, then a layer of minced meat and, finally, a layer of dough. Cover everything with the mixture of cream and Béchamel and sprinkle with grated cheese.
Bake in the oven, previously heated to 180º C, for 20 to 25 minutes.
More an idea of minced meat with dough, which will allow you to vary the presentation of your final dish.
The recipe is from the blog the Alchemy of Pots.
Salt, pepper or piri-piri q. b.
Salt, pepper and nutmeg q. b.
Cheese Mozzarella grated, oregano and basil q. b.
Start with the white sauce. Heat the milk and water in a pan and when boiling add a little salt, nutmeg and pepper.
Then, in a frying pan melt the butter and incorporate it with the flour to prevent the béchamel stay with clumping.
Join this prepared the steamed milk and stir with a wire whisk. When the sauce comes to a boil and thickens, remove from the heat.
Now is the time for the filling of the flesh. Heat a pan with the olive oil, the onion, the garlic and the bay leaf and let cook until the onion is slightly golden.
Then, add the meat, stir well and season with salt and pepper. Cook and stir, so the meat if you loosen and stay young.
Then add the wine, the pulp of tomato and bring to the boil.
Dissolve the bouillon in water and add slowly to meat, stirring so that everything would connect.
Let cook, on medium heat, stirring once in a while. Almost at the end add the parsley.If necessary, check the seasoning. Turn off and set aside.
Place the dough in plenty of boiling water and cook for about 11 minutes.
When it is baked, fill the shells with the minced meat, cover with the white sauce and sprinkle with the grated cheese. Sprinkle of oregano (optional) and bake in the oven, pre-heated to 220ºC for about 20 minutes or until it is baked.
Blog King of the Scoop arrives at a proposal minced meat with dough that will not disappoint. After all, the mass does not always have to be spaghetti!
First prepare the sauce. Chop an onion and heat it with the olive oil, until golden brown.
Then add the tomatoes, crushed and seasoned with salt and pepper, ground at the time. Cook on a moderate pace, for about 20 minutes.
Finally, add the parsley and winter savory, chopped, and leave to investigate for a further 10 minutes.
Then, pass the stuffing. Chop an onion and sauté in olive oil. When the onion turns transparent, add the meat, the chicken broth and let it cook for 20 minutes. Season with salt and pepper.
Then, add the sausages (without the skin) and spinach, previously picked, washed and chopped, and let sauté everything for about minutes.
Remove from the heat and add the beaten eggs.
Soak the cannelloni a few seconds in water seasoned with salt, pass them through cold water and fill with the prepared meat.
the with grated cheese and bake in the oven, previously heated for about 20 minutes.
To spice up your recipes here is this proposal is typical of real minced meat with pasta.
Sweet paprika, cayenne pepper, chilli (optional), olive oil, coriander, pepper and salt q. b.
Start by chopping all the vegetables into small cubes.
Then, in a frying pan put the onion, the garlic, the red pepper, with a drizzle of olive oil and let it cook.
In the meantime put the spaghetti to cook in a pan with plenty of hot water, with a pinch of salt and a drizzle of olive oil.
When the onion is transparent, add the minced meat and let it cook until you win color.
Then add the tomato chopped, the sauce, the paprika, the cayenne pepper, pepper, salt and a little chilli and let it cook.
If necessary, rectify the seasoning and, finally, add the chopped coriander. Drain the spaghetti and serve everything together.


The code is up to date as far as I can see although it's not really needed with version 2.4.x of the Advanced Guestbook.
Settings, style, entries etc are all stored in your database. You just ned to download 2.4.2, copy the database information from your 2.3.1 config.inc.php file to the 2.4.2 config.inc.php file then upload 2.4.2 and visit misc/update_db.php in your web browser.
No yo ucopy the database information FROM your current config.inc.php file TO the one in 2.4.2 as it has some new stuff in it.
can someone please take a look at my guestbook and help me out?
This mod is not needed for AG versions 2.4 and over as it has captha. Replace all your files except config.inc.php with the new ones.
I do not believe this is a case. Advanced Guestook I am using is 2.3.1.
"1146 Table 'guestbook.book_captcha' doesn't exist"
"1044 Access denied for user 'yscr_gbuAj7'@'localhost' to database 'guestbook'"
Once you update you need to visit the misc/update_db.php file in your web browser.


This text is machine-read, and may contain errors. Check the original document to verify accuracy.
envelopes or any publications, including publications and correspondence from Plaintiff PLN.
(civil rights), as this action seeks redress for civil rights violations under 42 U.S.C. § 1983.
pursuant to 28 U.S.C. §§ 2201 and 2202, and Rule 57 of the Federal Rules of Civil Procedure.
pursuant to 42 U.S.C. § 1983.
rise to the claim occurred in this District.
Rule 65, Federal Rules of Civil Procedure.
Country. PLN also maintains a website (www.prisonlegalnews.org) and operates an email list.
intended beneficiaries of PLN's activities. PLN seeks injunctive relief and damages.
reflected in Standard Operating Procedure 810.00 (entitled Inmate Mail).
postcard is 4.25 inches by 6.0 inches.
Bible, 12 colored pencils, and 1 sketchpad.
inmates, including Prison Legal News, Information Packets, and books.
Defendant's Postcard Policy is unconstitutionally overbroad.
interest in topics included in the magazine.
the highest protection afforded by the U.S. Constitution.
court rulings, the management of prison and jail facilities, and conditions of confinement.
Periodical" sticker with the box for "Refused" checked.
rejected and not delivered to its intended recipient.
and not delivered to their intended recipients.
Legal News each month. Each copy was individually addressed to the specific inmate-subscriber.
inmates were in custody at the time the Jail received the monthly journals.
opportunity to appeal the rejection of PLN's mail.
subscribers in the Jail each month.
Prison Legal News, enclosed in standard 9 inch by 12 inch manila envelopes, to inmates in the Jail.
copies were also rejected and not delivered to their intended recipients.
appeal the rejection of PLN's mail.
in a standard while #10 envelope.
Who Makes Money from Mass Incarceration—and other information about PLN's bookstore.
searching for a job, crime and poverty, and the mental health crisis in U.S. prisons and jails.
Information Packets and did not deliver them to their intended recipients.
se in litigating cases about the conditions of their confinement.
frustrate, PLN's organizational mission and have caused PLN to divert its resources.
books, Information Packets, and other materials to inmates in the Jail in the future.
speech, enjoying the highest protection under the First Amendment.
be irreparably harmed by the Sheriff's denial of its fundamental constitutional right to free speech.
Grant Plaintiff such other and further relief as may be just and equitable.
Plaintiff demands a trial by jury on all issues that can be heard by a jury.
Randall C. Berg, Jr., Esq.
s/ Randall C. Berg, Jr. .
also the founder and Executive Director of the HRDC.
to be true and accurate to the best of my knowledge and belief.
I understand that a false statement in this declaration will subject me to penalties for perjury.
I declare under penalty of perjury that the foregoing is true and correct.


text:
Q: PHP/MySql - Creating navigation buttons I'm totally stuck! I need to create navigation buttons in order to go through records that match a specific Id. So far I have only been able to retrieve 1 record (the first one). I am using the following code to do so:
$query = "SELECT t1.requester_name, t1.requester_email, t1.client_name, t1.client_country, t1.machine_quantity, t1.severity, t1.sales_connect, t1.request_status, t2.serial_type, t2.serial_model, t2.serial_number, t2.machine_status, t2.machine_config, t2.brand, t2.tier, t2.request_id
FROM requests t1
LEFT JOIN serialnumbers t2
ON t1.request_id = t2.request_id
WHERE t1.request_id = {$id} ";

$results = mysql_query($query, $connection);
$row = mysql_fetch_assoc($results);

The records are coming from 2 distinct tables and while I am having no trouble with the Request Table (Always one row), I cannot manage to figure out how to get every row in the Serial Numbers table (one to many relationship).
I am using a html form to display these values... Here is a sample of how I am doing so:
<input type="text" value="<?php echo $row['serial_type']; ?>" id="machineType" name="machineType[]" />

Any ideas on how I can achieve this objective?

A: you are going to want to make your $row = mysql_fetch_assoc a while loop.
while ($row = mysql_fetch_assoc($results)){
    echo '<input type="text" value="'.$row['serial-type']." id="machineType" name="machineType[]" />';
}

something along those lines.


text:
Bubach ist ein Gemeindeteil der Gemeinde Mamming im niederbayerischen Landkreis Dingolfing-Landau. Bis  1972 bildete es eine selbstständige Gemeinde.

Lage
Das Kirchdorf Bubach liegt im Isar-Inn-Hügelland am gleichnamigen Bach etwa zwei Kilometer südöstlich von Mamming.

Geschichte
Die Ruralgemeinde Bubach des Landgerichts Landau an der Isar wurde 1818 gebildet, aber bereits 1823 wieder aufgelöst und nach Mamming eingegliedert. Am 21. Oktober 1840 wurde sie jedoch wiedererrichtet, unter Einschluss der 1823 nach Mamming eingegliederten Ortschaften Adlkofen, Graflkofen, Hirnkofen (ehem. Gemeinde Graflkofen), Kuttenkofen und Ruhsam (von der Gemeinde Griesbach). Sie gehörte dann zum 1862 gebildeten Bezirksamt Dingolfing, aus dem 1939 der Landkreis Dingolfing wurde. Die Gemeinde umfasste die Dörfer Berg, Bubach und Dittenkofen sowie die Einöden Attenberg und Schneiderberg. Im Zuge der Gebietsreform in Bayern wurde sie am 1. Januar 1972 in die Gemeinde Mamming eingegliedert.

Sehenswürdigkeiten
 Benefiziumskirche St. Peter. Das romanische Langhaus und der Turm stammen vermutlich aus dem 12./13. Jahrhundert. Der Chor ist spätgotisch und wurde in der zweiten Hälfte des 15. Jahrhunderts erbaut. Im 17. und 18. Jahrhundert kamen barocke Veränderungen dazu. Bei der Renovierung 1959/1960 wurde eine Kreuzigungsgruppe des Regensburger Künstlers Guido Martini angebracht, die frei über dem Tabernakel hängt. Leopold Hafner gestaltete 2004 den Altarraum neu und schuf den jetzigen Ambo, den Altar und die Tabernakelstehle. Im Oktober 2006 kam eine neue Orgel zur Aufstellung.
 Waldkapelle Groafrauerl

Bildung und Erziehung
 Schule Bubach der Grund- und Mittelschule Mamming-Gottfrieding

Vereine
 Bayerischer Bauernverband, Ortsgruppe Bubach
 BBV - Landfrauen Bubach
 Brandschadenhilfsverein Mamming/Bubach
 Freiwillige Feuerwehr Bubach
 Jagdgenossenschaft Bubach
 Krieger- und Soldatenkameradschaft Bubach
 Waldbauernvereinigung Landau a.d.Isar, Ortsverband Bubach
 Unpolitische Wählergemeinschaft Bubach

Literatur
 Otto Helwig: Das Landgericht Landau an der Isar. Historischer Atlas von Bayern I/XXX, München 1972, ISBN 3 7696 9876 2

Weblinks

 Benefiziumskirche St. Peter in Bubach

Ort im Landkreis Dingolfing-Landau
Ehemalige Gemeinde (Landkreis Dingolfing-Landau)
Gemeindegründung 1818
Gemeindeauflösung 1972
Mamming
Kirchdorf (Siedlungstyp)

redpajama_set_name: RedPajamaWikipedia


This Saturday we drove to Toronto for the opening of the Scotiabank Nuit Blanche* Group Show at The Elaine Fleck Gallery. After a 7 hour drive (yeah, normally it's about 6 hrs but we ran into some traffic on the way... roadworks... sigh...), a quick dinner at a cool TexMex place and a coffee at the White Squirrel, we walked over to the gallery, which is located on 888 Queen West Street.
The event started at 7pm and it was already getting dark. We approached the gallery from across the street and the first thing I saw through the windows was my painting 'Summer Stroll' which, because of the lighting and the high contrast, seemed to jump off the wall! So Cool!
The Elaine Fleck Gallery has a very nice mix of brick and white walls. My piece was placed on a piece of the brick wall, which worked really, really well. Group shows like this can sometimes be a little crowded or all over the place but this show is really, really well curated, everything just flowed.
I've attended quite a few opening nights (or vernissages as well call them here in Montréal), I have some experience, but The Elaine Fleck Gallery is one of the top galleries in Toronto so I was a little nervous. Totally unnecessary of course! Everyone was super nice! I was greeted warmly by the gallery owner and felt right at home! I met some amazing artists who I definitely hope to meet again and had an awesome time!
All too soon it was time to say goodbye and find our hotel, which was located near the airport because of insanely high rates in the downtown area. When we arrived at our hotel we got another nice surprise, a free upgrade to a suite with hot-tub! Score! That was a nice treat! Usually I'm not a soaker tub person but a little soak in the hot tub after a 7 hour drive is pretty awesome!
The Scotiabank Nuit Blanche Group Show will be up for another two weeks (until October 18, 2015) so if you're in the Toronto area you should definitely go check it out! The Elaine Fleck Gallery is located at 888 Queen West Street. The show includes works by Amy Shackleton, Kathy Kissik, Lloyd Arbour, Karen Colangelo, Kristyn Watterworth, Jaqueline Veltri, Corin Ford Forrester and many other talented artists who's work was featured in the Fleck Fine Art Fall/Winter 2015 Catalogue.
* Nuit Blanche is an annual all-night or night-time arts festival. A Nuit Blanche will typically have museums, private and public art galleries, and other cultural institutions open and free of charge, with the centre of the city itself being turned into a de facto art gallery, providing space for art installations, performances (music, film, dance, performance art), themed social gatherings, and other activities.


text:
Oct-1999 Oxygen uptake kinetics during exercise in humans in relation to muscle blood flow Hughson, Richard L.; Hughson, Richard L.; Cardiorespiratory and Vascular Dynamics, Laboratory, Department of Kinesiology, University of Waterloo,Canada; Cardiorespiratory and Vascular Dynamics, Laboratory, Department of Kinesiology, University of Waterloo,Waterloo,Canada
Oct-2006 Oxygenation and Energetics of the Human Skeletal Muscle During Elevated Energy Demand Hamaoka, Takafumi; Kurosawa, Yuko; Osada, Takuya; Sako, Takayuki; Higuchi, Hiroyuki; Nishio, Shinya; Murase, Norio; Katsumura, Toshihito; Hamaoka, Takafumi; Kurosawa, Yuko; Osada, Takuya; Sako, Takayuki; Higuchi, Hiroyuki; Nishio, Shinya; Murase, Norio; Katsumura, Toshihito; Department of Sports Performance,National Institute of Fitness and Sports; Department of Sports Medicine for Health Promotion,Tokyo Medical University; Department of Neurology,University of Cincinnati; Department of Food & Nutrition,Japan Women's University; Department of Sports Performance, National Institute of Fitness and Sports; Department of Sports Medicine for Health Promotion, Tokyo Medical University; Department Neurology, University of Cincinnati; Department of Food & Nutrition, Japan Women's University
Oct-1996 Peripheral Circulatory Modulation in the Non-exercising Forearm during Contralateral Handgrip Exercise Alone and Combined with Leg Exercise Kagaya, Atsuko; Homma, Sachiko; Homma, Toshiyuki; Kagaya, Atsuko; Homma, Sachiko; Homma, Toshiyuki; Professor, Research Institute of Physical Fitness; Research assistant, Research Institute of Physical Fitness; Graduate student, Graduate course of Japan Women's College of Physical Education; Professor, Research Institute of Physical Fitness; Research assistant, Research Institute of Physical Fitness; Graduate student, Graduate course of Japan Women's College of Physical Education
Oct-1992 Peripheral Circulatory Readjustment to Superimposition of Rhythmic Handgrip Exercise to Plantar Flexion of Different Duration Kagaya, Atsuko; Ogita, Futoshi; Kagaya, Atsuko; Ogita, Futoshi; Professor at Research Institute of Physical Fitness; Research assistant at Research Institute of Physical Fitness; Professor at Research Institute of Physical Fitness; Research assistant at Research Institute of Physical Fitness


text:
Jamal Khashoggi Continues to Haunt the World's Conscience
One year after his grisly execution by a hit squad, the memory of journalist Jamal Khashoggi and his aspirations for the people of Saudi Arabia haunt the world's collective conscience.
A senior Turkish official says Turkey and Saudi Arabia will form a "joint working group" to look into the disappearance of Saudi writer Jamal Khashoggi.12 SEPTEMBER 2018 istanbu at Turkey
Gary Grappo
On October 2, 2018, Jamal Khashoggi, a Saudi expatriate journalist, walked into the Saudi Consulate in Istanbul. What then transpired resembled a 1920s American gangland-style killing, complete with the victim's final pleadings, the executioners' harsh words and the chilling sound of a bone saw dismembering the body.
We are fittingly reminded of the events of that horrific day by admirable reporting by the world media but none more so than The Washington Post, for which Khashoggi wrote on a semi-regular basis. On this anniversary, other media have come forward with their own memorials and reporting, including a CBS 60 Minutes interview with Saudi Crown Prince Mohammed bin Salman (MBS), a two-hour PBS Frontline exposé on the incident and the crown prince's role, and an especially powerful tribute in Time by Khashoggi's fiancée, Hatice Cengiz.
Repressions Persists
Many others around the world are doing the same. When a government sets out to eliminate a journalist for writing critiques of that government, the world media and governments that embrace free speech must speak out. But as despicably brutal as Jamal Khashoggi's murder was, we must not forget that 55 other journalists were killed in 2018 and 16 so far in 2019, according to the Committee to Protect Journalists. Khashoggi was but a symptom, while the disease of official, ruthless government repression of free speech persists.
Scroll down to read more on this 360° series
Aside from the media's commendable effort to keep the memory of Khashoggi alive, two things are particularly striking after one year. First, the event has become the definitive signpost of Saudi Arabia's undeniable descent into abject authoritarianism. The government and MBS continue to maintain the crown prince's innocence in the murder. The CIA, the UN special rapporteur and the US Senate insist otherwise, arguing that in Saudi Arabia's hyper-hierarchical decision-making structure, the hit could not have occurred without the knowledge of or authorization by Mohammed bin Salman.
The crown prince is the de facto leader of Saudi Arabia. He controls economic and oil policies, all the armed forces, the security and intelligence forces, and has completely marginalized the rest of the Saud senior princes — all a first in the 87-year-old kingdom's history since its founder, Abdul Aziz al-Saud. The fact that MBS may accept responsibility for the murder obfuscates his continuing refusal to admit he either ordered or was aware of it beforehand. His explanation follows several ludicrously mendacious versions touted by the Saudi government since last year, all disproven by subsequent revelations. Even US President Donald Trump couldn't help describing these pathetic attempts as "the worst cover-up in the history of cover-ups."
Meanwhile, a court case against some of the accused reportedly proceeds in secret. The whereabouts of others implicated in the killing, including MBS' close aide Saud al-Qahtani, remain unknown. If justice is ever done — increasingly unlikely given current circumstances — to any of those involved, the world will probably never know.
Khashoggi's murder should not distract us from the ongoing persecution and imprisonment of Saudi women, dissidents, bloggers and others who have also bravely spoken out against the crown prince's newly-established authoritarianism. Khashoggi once wrote: "Saudi Arabia wasn't always this repressive. Now it's unbearable." The sister of an imprisoned Saudi women's rights advocate underscores Khashoggi's fear, describing the kingdom today as a "police state."
During the violent rampage of al-Qaeda in the kingdom between 2003 and 2005, Saudi citizens trusted their security forces to protect them and ferret out the terrorists. The task was far from easy.
At that time, I was serving as deputy ambassador at the US Embassy in the kingdom. In the course of one incident — one of many that had sent residents into abject panic for their lives — when Saudi authorities suspected that terrorists were hiding in a particular neighborhood of Riyadh, I asked a senior official if they had considered a house-to-house search. His response impressed me: "We cannot violate the privacy and dignity of Saudi households without evidence." In Mohammed bin Salman's Saudi Arabia, the days of household sanctity or personal dignity are things of the past.
The world should not be confused by MBS' so-called cultural liberation of the kingdom — the outdoor concerts, newly-opened movie theaters, women driving and lowered religious policing — or ambitious economic plans. They are his version of Rome's "bread and circuses." Politics — whether a misbegotten war in Yemen, roundup and shakedown of influential businessmen and officials in a Riyadh luxury hotel, harmless blogs on social media or genuine freedom for Saudi women — are strictly off-limits. Discussion of such matters is punishable by imprisonment, torture or even death. It's the Vladimir Putin and Xi Jinping models, MBS-style.
American Betrayal
The second factor lingering from Khashoggi's tragic death is the perhaps equally tragic silence of the country that he hoped Saudi Arabia would one day come to emulate, the United States. Under President Trump and Secretary of State Mike Pompeo, America is vitiating one of its founding principles: free speech. Trump and Pompeo have gone to great pains to shield MBS from an increasingly vociferous Congress not yet ready to surrender its values. The president ostensibly has done it for billions of dollars in military weapons sales to Saudi Arabia, the modern-day version of 30 pieces of silver.
The Trump administration's position remains all the more perplexing in light of the findings of the CIA and unanimous consent of the Senate as to the guilt of MBS. It would seem that the president is as impervious to America's institutions as he is to its values.
Jamal Khashoggi's death may serve as a signpost too for the US as it confronts the rise of authoritarianism worldwide. Should Moscow, Tehran, Damascus, Beijing, Budapest, Warsaw, Cairo, Manila, Caracas, Managua and Riyadh all take heart now in their new-found friend in the heart of liberty and democracy, the US? If so, then we should expect many more deaths to follow. Which might be just what the authoritarians are wishing for. In the words of the modern era's authoritarian role model, Joseph Stalin, "A single death is a tragedy; a million deaths is a statistic."
Before one journalist's brutal death is relegated to a statistic, we should remind ourselves of the ideals he stood for, wrote about and dreamed for his fellow Saudis and for all the people of the Middle East. Those are the reasons that Mohammed bin Salman wanted his life extinguished. But, of course, ideas cannot be extinguished. As long as Saudi Arabia, the US and other governments turn away from his death, the longer all peoples struggling for genuine freedom shall be haunted by it.
Jamal Khashoggi's Murder Damages Press Freedom
Atul Singh • October 02, 2019
Are Saudi Arabia and MBS Becoming a Liability for the White House?
Gary Grappo • December 18, 2018
The Walls Are Closing in on Free Media in the Arab World
Bill Law • November 08, 2018
Jamal Khashoggi Shines Light on Arts Sector's Problem with Money
Vanessa Stevens • November 07, 2018
Continuing Jamal Khashoggi's Fight for Free Expression in the Arab World
Rasheed Alameer • October 26, 2018
Why Erdogan Had to Act on Khashoggi Killing
Nathaniel Handy • October 24, 2018
Can the Murder of Jamal Khashoggi Help Bring an End to the War in Yemen?
Bill Law • October 22, 2018
Jamal Khashoggi: The Martyr Who Made Backlash Possible
Peter Isackson • October 19, 2018
Assassins Without Borders
John Feffer • October 19, 2018
The US Is in Unchartered Territory with Saudi Arabia
Gary Grappo • October 18, 2018
The Death of One Man Is a Tragedy
Virgil Hawkins • October 16, 2018
Is Jamal Khashoggi Really Dead?
The Disappearance of Jamal Khashoggi Confirms a Dangerous Trend


text:
General Staff to receive assistance from international lawyers on investigating crimes in occupied areas
posted 16 November 2016 10:15
Defense Policy International activity
"The Armed Forces of Ukraine are counting on help of international lawyers in spreading knowledge of international humanitarian law among the personnel of the Armed Forces, as well as the collection and systematization of information to be provided to the International criminal court to bring to justice the perpetrators of war crimes in the occupied territories Ukraine."
General of the Army of Ukraine Viktor Muzhenko, Chief of General Staff of the Ukrainian Armed Forces, said that during a meeting with leading international and Ukrainian lawyers, held by the initiative of the General Staff yesterday, November 15.
The meeting was attended by managing partners of the international law of Global Rights Compliance Wayne Dzhordash (UK) and Scott Martin (USA), as well as leading Ukrainian lawyers from the Institute of International Relations of Kyiv National Taras Shevchenko University who represent Ukraine in the international human rights arena.
Volodymyr Groysman urges to fight for Ukraine, for reforms every day
Fitch raises the rating of Ukraine to "В-" with a stable forecast
By themes «Defense», «Policy», «International activity»
11:54, 15 July International activity Social policy Minister of Social Policy Andrii Reva to take part in the High-Level Political Forum on Sustainable Development in New York


text:
Canada's Involvement in International Human Rights
By hadleyP
The Universal Declaration of Human Rights
This document was created and signed by the United Nations to strengthen the idea of the basic rights of citizens of the world in a physical, readable form. John Humphrey, played an important role in the writing of the UDHR.
The Creation of Human Rights Day
The United Nations (which includes Canada) decided to offer the countries of the world the opportunity to participate in a holiday, Human Rights Day, on December 10th of every year. On that day, the Universal Declaration of Human Rights is celebrated and an important human rights issue issue is focused on and talked about.
UN Peacekeeping Force in Cyprus
In 1964, the UN sent troops to Cyprus to prevent the Turkish and Greek Cypriots from fighting further, ensure their safety ans return them to their everyday lives. Canada was part of this mission. Peacekeepers were sent in after an "outbreak of violence on the island in 1963. (Ignore month and day, that information was unavailable).
Convention on the Elimination of All Forms of Discrimination Against Women
This was adopted by the UN General Assembly. It was basically clarifying that women should be treated as equals to men and not be discriminated against.
Canada ratifies the CRC
The CRC, or Convention on the Rights of the Child, was put together by the United Nations. This document basically states the human rights of people 18 years old and younger, or kids. Canada signed the CRC on May 28th, 1990 and ratified it on this date.
Vienna World Conference on Human Rights
This conference was held in Vienna, Austria and two weeks long. Representatives from 171 different States, including Canada, participated. The purpose of the conference was to strengthen international peacekeeping efforts by coming up with a common plan. By the end of the conference, a consensus was reached - the Vienna Declaration and Programme of Action.
World Conference Against Racism
This conference, Held in Durban, South Africa, was a UN meeting to discuss "racism, racial discrimination, xenophobia, and related intolerance". Canada participated, as did all other member states of the United Nations.
UNMIS (United Nations Mission in the Sudan
On this date, the UN decided to send troops to Sudan to make sure that the peace agreement was implemented, for humanitarian assistance, and for the "protection and promotion of human rights".
Establishment of the United Nations Human Rights Council
The council was created for the "promotion and protection of human rights around the globe". Canada is part of the HRC.
Intervention Brigade in Congo
Due to violence in Congo, an intervention brigade was sent in to protect civilians, humanitarian personnel and human rights defernders as they were under threat of violence. The brigade also had to help the government of Congo to attain peace and stabilize the situation. http://www.edu.gov.mb.ca/k12/cur/socstud/foundation_gr6/blms/6-3-4b.pdf
Canadian and the World (1914-1945)
Comparative Timeline
SS11 Invergarry - Canada's Autonomy
Canada - 1100 years of history
Canada in the 1920's
Québec - Canada Timeline
Canada 1945-2000
Canada in Afghanistan: 2001 to 2011
Canada's involvement in international human rights protection since WWII
The life of 1800
Canada 100 Days
Canada: 1945 - 2000
Canada Timeline: 1960s
Canadian History Timeline
1920s Canada
Canada: 1945-2000
Hi 30 Timeline Challenge TennyKyra
canada in 1930s
mr.knodel project
HI 30 Timeline Challenge BrettIbrahim
Decade Report 1970s
Canadian History 1920s & 1930s
Somewhere Over the LGBTQ Rainbow
Canada in the 1920s
Hi 30 Timeline Challenge AmyJohn


It's always Halloween inside this The Nightmare Before Christmas double-mirrored compact mirror.
The Nightmare Before Christmas Now And Forever Double Sided Compact Mirror is rated 5.0 out of 5 by 3.
Rated 5 out of 5 by Jmejayhawk from Adorable! Bought this for my daughter who is a huge fan! It is adorable!
Rated 5 out of 5 by Anne0105 from My Sister Loves It! I purchased this mirror as a birthday gift for my sister and she absolutely loves it.
Rated 5 out of 5 by Mystics from Élégant ! I love it, very easy to open, big enough and yet slim enough to fit in a tiny purse Love that one side enlarge !


Music search, retrieval, and recommendation systems have experienced a boom during the past few years due to streaming services providing access to huge catalogs anywhere and anytime. These streaming services collect the user behavior in terms of actions on music items, such as play, skip, playlist creation and modification. As a result, an abundance of user and usage data has been collected and is available to companies and academics, allowing for user profiling and to create personalized music search and recommendation systems. The importance and timeliness of research on such personalized music systems is evidenced by publications in venues including RecSys, UMAP, ISMIR, CHI, and IUI, as well as in journals including IEEE Transactions on Affective Computing and ACM Transactions on Intelligent Systems and Technology.
On the other hand, there are still plenty of unsolved challenges. In particular, scholars have identified as some of the most vital ones: user understanding and modeling, personalization of recommendation and retrieval systems, user adaptivity in interfaces, and context-awareness.
With this Special Issue, we intend to establish a high-impact forum for latest research on user modeling and personalization for finding, making, and interacting with music. We invite researchers from both academia and industry to submit their original excellent research on these topics.
The following represents a non-exhaustive list of topics. We solicit manuscripts covering all aspects of user modeling for adaptive and personalized music algorithms and applications, in particular for music search and recommendation. These include, but are not limited to the following general categories: models of music consumption, algorithms for personalization and recommendation, interfaces and interaction, and evaluation.
If you are unsure whether your topics fits, please contact the guest editors (see below).
Authors must submit an extended abstract via EasyChair by the deadline indicated above. It must be at most 3 pages long, not counting references, and formatted according to the journal template. The guest editors of the special issue will then screen all submitted extended abstracts and will invite authors of submissions that pass this screening to submit a full manuscript to be submitted via the journal's submission system.


text:
// Copyright (c) 2006-2007 Frank Laub
// All rights reserved.

// Redistribution and use in source and binary forms, with or without
// modification, are permitted provided that the following conditions
// are met:
// 1. Redistributions of source code must retain the above copyright
//    notice, this list of conditions and the following disclaimer.
// 2. Redistributions in binary form must reproduce the above copyright
//    notice, this list of conditions and the following disclaimer in the
//    documentation and/or other materials provided with the distribution.
// 3. The name of the author may not be used to endorse or promote products
//    derived from this software without specific prior written permission.
//
// THIS SOFTWARE IS PROVIDED BY THE AUTHOR ``AS IS'' AND ANY EXPRESS OR
// IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, THE IMPLIED WARRANTIES
// OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE ARE DISCLAIMED.
// IN NO EVENT SHALL THE AUTHOR BE LIABLE FOR ANY DIRECT, INDIRECT,
// INCIDENTAL, SPECIAL, EXEMPLARY, OR CONSEQUENTIAL DAMAGES (INCLUDING, BUT
// NOT LIMITED TO, PROCUREMENT OF SUBSTITUTE GOODS OR SERVICES; LOSS OF USE,
// DATA, OR PROFITS; OR BUSINESS INTERRUPTION) HOWEVER CAUSED AND ON ANY
// THEORY OF LIABILITY, WHETHER IN CONTRACT, STRICT LIABILITY, OR TORT
// (INCLUDING NEGLIGENCE OR OTHERWISE) ARISING IN ANY WAY OUT OF THE USE OF
// THIS SOFTWARE, EVEN IF ADVISED OF THE POSSIBILITY OF SUCH DAMAGE.

using System;
using System.Collections.Generic;
using System.Text;
using OpenSSL;

namespace test
{
	class TestRandom : ICommand
	{
		#region ICommand Members

		public void Execute(string[] args)
		{
			Console.WriteLine("Testing random");
			int err = 0;

			byte[] buf = OpenSSL.Core.Random.PseudoBytes(2500);

			uint n1 = 0;
			uint[] n2 = new uint[16];
			uint[,] runs = new uint[2, 34];

			int sign = 0;
			int nsign = 0;

			for (int i = 0; i < buf.Length; i++)
			{
				int j = buf[i];

				n2[j & 0x0f]++;
				n2[(j >> 4) & 0x0f]++;

				for (int k = 0; k < 8; k++)
				{
					int s = (j & 0x01);
					if (s == sign)
						nsign++;
					else
					{
						if (nsign > 34)
							nsign = 34;
						if (nsign != 0)
						{
							runs[sign, nsign - 1]++;
							if (nsign > 6)
								runs[sign, 5]++;
						}
						sign = s;
						nsign = 1;
					}

					if (s != 0) n1++;
					j >>= 1;
				}
			}
			if (nsign > 34)
				nsign = 34;
			if (nsign != 0)
				runs[sign, nsign - 1]++;

			#region Test 1
			if (!((9654 < n1) && (n1 < 10346)))
			{
				Console.WriteLine("test 1 failed, X={0}", n1);
				err++;
			}
			Console.WriteLine("test 1 done");
			#endregion

			#region Test 2
			uint d = 0;
			for (int i = 0; i < 16; i++)
				d += n2[i] * n2[i];
			d = (d * 8) / 25 - 500000;
			if (!((103 < d) && (d < 5740)))
			{
				Console.WriteLine("test 2 failed, X={0}.{1}", d / 100, d % 100);
				err++;
			}
			Console.WriteLine("test 2 done");
			#endregion

			#region Test 3
			for (int i = 0; i < 2; i++)
			{
				if (!((2267 < runs[i, 0]) && (runs[i, 0] < 2733)))
				{
					Console.WriteLine("test 3 failed, bit={0} run={1} num={2}", i, 1, runs[i, 0]);
					err++;
				}
				if (!((1079 < runs[i, 1]) && (runs[i, 1] < 1421)))
				{
					Console.WriteLine("test 3 failed, bit={0} run={1} num={2}", i, 2, runs[i, 1]);
					err++;
				}
				if (!((502 < runs[i, 2]) && (runs[i, 2] < 748)))
				{
					Console.WriteLine("test 3 failed, bit={0} run={1} num={2}", i, 3, runs[i, 2]);
					err++;
				}
				if (!((223 < runs[i, 3]) && (runs[i, 3] < 402)))
				{
					Console.WriteLine("test 3 failed, bit={0} run={1} num={2}", i, 4, runs[i, 3]);
					err++;
				}
				if (!((90 < runs[i, 4]) && (runs[i, 4] < 223)))
				{
					Console.WriteLine("test 3 failed, bit={0} run={1} num={0}", i, 5, runs[i, 4]);
					err++;
				}
				if (!((90 < runs[i, 5]) && (runs[i, 5] < 223)))
				{
					Console.WriteLine("test 3 failed, bit={0} run={1} num={2}", i, 6, runs[i, 5]);
					err++;
				}
			}
			Console.WriteLine("test 3 done");

			#endregion

			#region Test 4
			if (runs[0, 33] != 0)
			{
				Console.WriteLine("test 4 failed, bit={0} run={1} num={2}", 0, 34, runs[0, 33]);
				err++;
			}
			if (runs[1, 33] != 0)
			{
				Console.WriteLine("test 4 failed, bit={0} run={1} num={2}", 1, 34, runs[1, 33]);
				err++;
			}
			Console.WriteLine("test 4 done");
			#endregion

			Console.WriteLine("done");
		}

		#endregion
	}
}

redpajama_set_name: RedPajamaGithub


Vsys Automation designs and integrates high end control systems, home theaters, lighting Control systems, integrated AV systems, robust networks for intelligent homes. Our commitment to quality services, equipment, attention to detail, and our client's satisfaction are the driving force to our success.
Vsys Automation is focused on automating homes to minimize the amount of work and responsibilities that the home owner has all while saving them time, energy and ultimately money. By using software uniquely designed to give users remote access to their residential systems from their office, or even while vacationing half way around the world, Giving the home owner more freedom to engage in day to day activities. By focusing on home automation we are creating a more energy efficient environment.
We work closely with Architects, Interior Designers, General Contractors, and homeowners. Our company can customize any system to fit your lifestyle or budget. The possibilities for your home are endless. We are your integration experts that you can trust.
Saving You Time, Energy, & Money.


Fulco Environmental Inc. is proud to announce we have a Licensed Toxic Reduction Planner on staff.
The Toxics Reduction Act (TRA) and the toxics reduction regulation (Reg. 455/09) apply to Ontario facilities where manufacturing activities or mineral processing activities take place and the facility is required to provide information under the National Pollutant Release Inventory (NPRI) or Ontario Regulation 127/01 - Airborne Contaminant Discharge Monitoring and Reporting. The purpose of the act is to track toxic substances as they move through facility operations, and to quantify the amount of each toxic substance that is used, created, destroyed, transferred or released in an effort to identify stages or processes at a facility that have the potential to reduce the use and creation of toxic substances.
The substances identified as toxic substances in Ontario Regulation 455/09 include all of the substances in the National Pollutant Release Inventory (NPRI) as well as acetone (Reg. 12701).
Preparation of the toxic reduction plan is mandatory. Implementation of the toxic reduction plan is voluntary, and progress is tracked through annual reviews and updates.
Forty-seven substances and substance groups were identified as priorities for inclusion in the initial regulatory requirements in 2010 and 2011 (Phase 1).
Phase 2, which includes all of the remaining substances on the NPRI list, came into effect January 1, 2012. Facilities that use these substances will be required to report and plan for these substances in 2013.
January 1, 2010 - Facilities are required to identify, track and quantify all Phase I substances used or created for each process.
June 17, 2011 – The first annual report for Phase I substances was due for the prescribed Toxic Substances.
June 29, 2012 – The second annual report for Phase I substances was due for the prescribed Toxic Substances.
December 31, 2012 – Toxic Substance Reduction Plans for each of the Phase I substances are due. All plans must be signed by a licensed Toxic Reduction Planner.
January 1, 2012 – Facilities are required to identify, track and quantify all Phase II substances used or created for each process.
June 1, 2013 – The first annual report for Phase II substances is due for the prescribed Toxic Substances.
December 31, 2013 – Toxic Substance Reduction Plans for each of the Phase II substances are due. All plans must be signed by a licensed Toxic Reduction Planner.
If you require any assistance our Licensed Toxic Reduction Planner will be happy to assist.
Please feel free to contact us for further information or to request a quotation and our team will be happy to assist you.


What if they played Daft Punk on Soul Train back in the 1970s? Nothing different than any other episode – so check out this perfectly timed dance mashup. Though there's no way you could fit one of those 'fros in a helmet.